已收盤 09-20 16:00:00 美东时间
-0.003
-1.29%
HC Wainwright & Co. analyst Sean Lee maintains Virios Therapeutics (NASDAQ:VIRI) with a Neutral and lowers the price target from $0.4 to $0.2.
08-10 05:19
Virios Therapeutics (NASDAQ:VIRI) reported quarterly losses of $(0.05) per share which met the analyst consensus estimate. This is a 37.5 percent increase over losses of $(0.08) per share from the same period last year.
08-08 21:23
Virios Therapeutics AnnouncesSecond Quarter 2024 Financial Results
08-08 21:15
Virios Therapeutics: Believes It Will Have Sufficient Resources to Fund Operati...
08-08 21:15
Virios Therapeutics Announces Completion of Enrollment in Imc-2 Phase 2 Long-Co...
07-23 21:15
Shares of Vuzix Corporation (NASDAQ:VUZI) rose sharply in today's pre-market tr...
06-20 20:22
Unity Software(U.US) reported fourth-quarter financial results after the market...
06-20 19:46
Virios Therapeutics Inc : Maxim Group Initiates Coverage WithBuy Rating; ...
06-20 19:36